

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
AUG 2 2003
TECH CENTER 1600/200
10/006,593Form PTO-1449 U.S. DEPARTMENT OF
COMMERCE PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

54 US

SERIAL NO.

10/006,593

APPLICANT

Bowdish et al.

FILING DATE

December 5, 2001

GROUP A UNIT:

1642

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LM	5 7 7 3 5 6 9	06/30/1998	Wrighton et al.	7	7	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
LM		0 0 2 4 7 8 2	05/04/2000	WO	7	7		
		0 0 6 1 6 3 7	10/19/2000	WO				
		9 9 1 0 4 9 4	03/04/1999	WO				
		9 9 2 5 3 7 8	05/27/1999	WO				
		9 6 4 0 1 8 9	12/19/1996	WO				
		9 5 1 1 3 1 7	04/27/1995	WO	7	7		
		9 5 2 9 6 9 0	11/09/1995	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LM	PCT Search Report PCTUS01/47636 4/03
LM	Alexandre Jagerschmidt, Human Thrombopoietin Structure-Function Relationships: Identification Of Functionally Important Residues, Biochem.J. (1998) 333, 729-734
LM	Takumi Kamura, Characterization of Human Thrombopoietin Gene Promoter, The Journal Of Biological Chemistry, 1997 by The American Society for Biochemistry and Molecular Biology, Inc., Vol. 272, No. 17, Issue of April 25, pp. 11361-11368, 1997.
LM	Jeremy Cook, Recombinant Antibodies Containing an Engineered B-Cell Epitope Capable Of Eliciting Conformation-Specific Antibody Responses, Butterworth Heinemann, Vaccine, Vol. 13, No. 18, pp. 1770-1778, 1995, Elsevier Science Ltd.
LM	Hayden M S ET AL, Antibody Engineering, current Opinion in Immunology, Current Biology Ltd, XX, Vol. 9, No. 2, April 1997, pp. 201-212.
LM	Parhami-Seren B. ET AL, Selection of High Affinity P-Azophenylarsonate Fab's From Heavy-Chain CDR2 Insertion Libraries, Journal of Immunological Methods, Elsevier Science Publishers B.V., Amsterdam, NL, Vol. 259, No. 1-2, January 1, 2002

EXAMINER

DATE CONSIDERED

12/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. DEPARTMENT OF
COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

54 US


10/006, 83

several sheets if necessary)

AUG 23 2003

TECH GENIC 1600/2000

RECEIVED



APPLICANT

Bowdish et al.

FILING DATE

December 5, 2001

GROUP A Unit:

1642

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chaiken I M et al., Identifying Structure-Function Relationships in Four-Helix Bundle Cytokines: Towards De Nova Mimetics Design, Trends in Biotechnology, Elsevier Publications, Cambridge, GB, Vol. 14, No. 10, October 1, 1996, pp 369-375.

EXAMINER

DATE CONSIDERED

12/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.